


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Lyka Labs Limited** (the "Company") for the quarter ended December 31, 2024 and year to date from April 1, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Regn No. 105335W




Deepak O. Narsaria
(Partner)
Membership No. 121190

UDIN: 25121190BMLLUJ9382

Place: Mumbai
Date: 4th February, 2025

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months Ended 31st December 2024

(₹ in lakh)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31st Dec 2024 (Unaudited)	30th Sep, 2024 (Unaudited)	31st Dec 2023 (Unaudited)	31st Dec 2024 (Unaudited)	31st Dec 2023 (Unaudited)	31st Mar, 2024 (Audited)
I. Revenue						
Revenue from Operations	3292.11	4115.51	3141.52	10418.09	7941.22	10639.63
Other Income	87.43	12.94	52.49	162.32	125.77	164.72
II. Total Income	3379.54	4128.45	3194.01	10580.41	8066.99	10804.35
III. Expenses						
(a) Cost of Materials Consumed	941.73	1020.38	902.10	2739.64	2350.55	3214.31
(b) Purchase of Stock in trade	320.28	821.73	296.97	1542.10	890.78	1158.47
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(3.07)	(47.60)	(23.50)	(78.76)	(87.78)	(78.61)
(d) Employee benefits expense	833.47	820.42	699.34	2457.39	1886.84	2601.46
(e) Finance Costs	61.62	51.73	125.89	178.42	376.29	479.79
(f) Depreciation and amortisation expense	175.44	168.34	271.68	511.48	951.54	1228.71
(g) Other expenses	691.12	966.63	681.37	2309.80	1666.32	2287.95
Total Expenses	3020.60	3801.63	2953.85	9660.08	8034.54	10892.08
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	358.94	326.82	240.16	920.33	32.45	(87.73)
V. Exceptional Items (Net)	0.00	0.00	0.00	0.00	4.52	5.51
VI. Profit / (Loss) before Tax	358.94	326.82	240.16	920.33	27.93	(93.24)
VII. Tax Expenses						
Current Tax	86.00	84.41	91.00	210.41	124.50	159.97
Deferred Tax	3.09	(4.88)	12.70	17.82	(31.81)	(26.32)
VIII. Net Profit / (Loss) after Tax	269.85	247.29	136.46	692.10	(64.76)	(226.89)
IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	0.00	0.00	(3.14)	0.00	(4.71)	6.17
X. Total Comprehensive Income / (Loss)	269.85	247.29	133.33	692.10	(69.47)	(220.72)
Paid up Equity Share Capital (Face value ₹ 10/- each)	3569.00	3569.00	3309.00	3569.00	3309.00	3309.00
Other Equity						6623.91
XI. Basic and diluted earnings per share	0.75	0.69	0.40	1.93	(0.22)	(0.72)

Notes:

- The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 04th February 2025
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited Standalone financials results for the quarter and Nine Month ended 31st December, 2024.



For Lyka Labs Limited

Kunal Gandhi
 Kunal Gandhi
 Managing Director & CEO
 DIN: 01516156

Ankleshwar : 04th February, 2025

Independent Auditor's Review Report on the Quarterly and Year-to-Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Lyka Labs Limited** ("the Parent"), which includes its subsidiaries (the Parent and its Subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2024 and year-to-date from April 1, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

- i) Lyka Labs Limited

Subsidiaries

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/ information reflects total assets of Rs. 839.67 lakhs as at December 31, 2024, total revenues of Rs. 189.64 lakhs and Rs. 209.67 lakhs, total net profit/ (loss) after tax of Rs. 0.54 lakhs and Rs. (101.64) lakhs and total comprehensive income of Rs. (1.21) lakhs and Rs. (101.64) lakhs, for the quarter ended December 31, 2024 and year-to-date from April 1, 2024 to December 31, 2024 respectively, and net cash inflow of Rs. 16.62 lakhs as at December 31, 2024, which have been reviewed by us.



6. Based on our review conducted and procedures performed as stated in para 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W



Deepak O. Narsaria
(Partner)
Membership No. 121190



UDIN: 25121190BMLL4K8241 .

Place: Mumbai
Date: 4th February, 2025

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Month Ended 31st December, 2024

Particulars	(₹ in lakhs)					
	Quarter Ended			Nine Month Ended		Year Ended
	31st December, 2024 (Unaudited)	30th September 2024 (Unaudited)	31st December, 2023 (Unaudited)	31st December, 2024 (Unaudited)	31st December, 2023 (Unaudited)	31st March, 2024 (Audited)
I. Revenue						
Revenue from Operations	3,379.76	4,115.51	3,256.38	10,506.67	8,342.73	11,119.46
Other Income	82.62	2.66	54.20	141.16	116.38	145.47
II. Total Income	3,462.38	4,118.17	3,310.58	10,647.83	8,459.11	11,264.93
III. Expenses						
(a) Cost of Materials Consumed	941.73	1,020.38	902.09	2,739.64	2,350.55	3,214.31
(b) Purchase of Stock in trade	367.33	821.73	289.39	1,589.82	1,025.32	1,349.36
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(3.07)	(47.60)	(23.54)	(78.76)	(87.94)	(78.50)
(d) Employee benefits expense	848.47	834.90	716.68	2,502.14	1,953.90	2,676.54
(e) Finance Costs	61.43	54.30	127.83	180.44	381.74	489.09
(f) Depreciation and amortisation expense	183.31	176.30	284.16	535.27	990.32	1,280.18
(g) Other expenses	705.96	990.92	685.32	2,368.58	1,732.22	2,386.27
Total Expenses	3,105.17	3,850.93	2,981.93	9,837.14	8,346.11	11,317.25
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	357.21	267.25	328.65	810.69	113.00	(52.32)
V. Exceptional Items (Net)	-	-	-	-	43.48	41.06
VI. Profit / (Loss) before Tax	357.21	267.25	328.65	810.69	69.52	(93.37)
VII. Non Controlling Interest	(0.43)	(18.52)	23.31	(33.58)	1.93	(13.12)
VIII. Profit / (Loss) before Tax	357.64	285.77	305.34	844.27	67.59	(80.25)
IX. Tax Expenses						
Current Tax / Earlier Year Tax	86.24	84.41	104.33	210.65	152.57	186.93
Deferred Tax	0.57	(8.29)	22.91	9.58	(29.76)	(18.26)
X. Net Profit / (Loss) after Tax	270.83	209.65	178.10	624.04	(55.22)	(248.92)
XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)						
Owners of the Parent	(1.55)	1.85	0.97	-	(1.30)	9.33
Non-controlling Interest	(0.21)	0.29	0.16	-	(0.17)	1.22
XII. Total Comprehensive Income / (Loss)	269.29	211.50	179.07	624.04	(56.52)	(239.59)
XIII. Paid up Equity Share Capital						
(Face value Rs.10/- each)	3,569.00	3,569.00	3,309.00	3,569.00	3,309.00	3,309.00
Other Equity						3,506.43
XIV. Basic and diluted earnings per share	0.75	0.58	0.53	1.74	(0.19)	(0.79)

Notes:

- The above unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 4th February 2025
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the Quarter and Nine Month ended 31st December 2024



For Lyka Labs Limited

Nunal Gandhi
Nunal Gandhi
Managing Director & CEO
DIN: 01516156

Ankleshwar : 04th February 2025